4D Molecular Therapeutics’ (FDMT) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a report released on Monday morning,Benzinga reports. They currently have a $36.00 price objective on the stock.

A number of other research analysts have also issued reports on the stock. Bank of America reduced their target price on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, February 19th. Morgan Stanley reduced their target price on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a report on Monday, January 13th. Leerink Partners dropped their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research note on Monday, January 13th. Finally, Royal Bank of Canada dropped their price objective on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.38.

4D Molecular Therapeutics Trading Up 4.8 %

NASDAQ:FDMT opened at $4.16 on Monday. The firm has a market cap of $192.31 million, a price-to-earnings ratio of -1.46 and a beta of 2.81. The company’s 50-day moving average is $5.12 and its two-hundred day moving average is $8.37. 4D Molecular Therapeutics has a 12-month low of $3.92 and a 12-month high of $36.25.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Friday, February 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). On average, equities research analysts forecast that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of FDMT. Millennium Management LLC increased its position in 4D Molecular Therapeutics by 1,607.1% during the 4th quarter. Millennium Management LLC now owns 1,420,723 shares of the company’s stock worth $7,913,000 after purchasing an additional 1,337,497 shares in the last quarter. Braidwell LP increased its position in 4D Molecular Therapeutics by 231.7% during the 3rd quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock worth $13,247,000 after purchasing an additional 855,990 shares in the last quarter. JPMorgan Chase & Co. increased its position in 4D Molecular Therapeutics by 159.5% during the 4th quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company’s stock worth $4,568,000 after purchasing an additional 504,086 shares in the last quarter. Norges Bank acquired a new stake in 4D Molecular Therapeutics during the 4th quarter worth approximately $2,790,000. Finally, Cubist Systematic Strategies LLC increased its position in 4D Molecular Therapeutics by 2,084.5% during the 4th quarter. Cubist Systematic Strategies LLC now owns 448,831 shares of the company’s stock worth $2,500,000 after purchasing an additional 428,285 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.